|
KMID : 1161520220260060275
|
|
Animal Cells and Systems
2022 Volume.26 No. 6 p.275 ~ p.282
|
|
|
Metabolic reprogramming as a novel therapeutic target for Coxsackievirus B3
|
|
Kuk Myeong-Uk
Ga Yun-Ji
Kim Ye-Jin
Park Ji-Yun
Song Eun-Seon
Lee Ha-Neur
Lee Yun-Haeng
Ko Ga-Hyun
Kim Jae-Kwang
Yeh Jung-Yong
Kwon Hyung-Wook
Byun Young-Joo
Park Joon-Tae
|
|
|
Abstract
|
|
|
|
Coxsackievirus B3 (CVB3) is a single-stranded RNA virus that belongs to the Enterovirus genus. CVB3 is a human pathogen associated with serious conditions such as myocarditis, dilated cardiomyopathy, and pancreatitis. However, there are no therapeutic interventions to treat CVB3 infections. In this study, we found that CVB3 induced metabolic alteration in host cells through increasing glycolysis level, as indicated by an increase in the extracellular acidification rate (ECAR). CVB3-mediated metabolic alteration was confirmed by metabolite change analysis using gas chromatography-mass spectrometry (GC-MS). Based on findings, a strategy to inhibit glycolysis has been proposed to treat CVB3 infection. Indeed, glycolysis inhibitors (2-Deoxy-D-glucose, sodium oxide) significantly reduced CVB3 titers after CVB3 infection, indicating that glycolysis inhibitors can be used as effective antiviral agents. Taken together, our results reveal a novel mechanism by which CVB3 infection is controlled by regulation of host cell metabolism.
|
|
|
KEYWORD
|
|
|
Coxsackievirus B3, metabolicalteration, glycolysisinhibitors, antiviral effect
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|